Indenoisoquinoline maximum dose established in relapsed solid tumors, lymphomas
Click Here to Manage Email Alerts
CHICAGO — Researchers presented the maximum dose for indenoisoquinoline LMP744 during the ASCO Annual Meeting, reporting prolonged stability in select patients.
The study, presented by Brian Ko, MD, was designed to establish the safety, efficacy and maximum tolerated dose of indenoisoquinoline LMP744 — a non-camptothecin inhibitor of topoisomerase 1 — previously shown most efficacious in animal studies. This multicenter phase 1 trial evaluated dose escalations in 24 adults with relapsed solid tumors and lymphomas, according to researchers.
“We were able to establish the maximum tolerated dose at 190 mg/m2/day. It’s dosed days 1 through 5 in a 28-day cycle,” Ko, an NCI clinical fellow, told Healio. “The single agent activity was limited, but the main thing we found was that particularly patients with colorectal cancer had prolonged stabilization of disease. Potentially this agent could be used in patients who have progressive metastatic disease.”
Of 23 evaluable patients, one achieved a partial response, 16 had stable disease and six had progressive disease, according to researchers. Analyses of secondary and exploratory correlatives are ongoing, Ko said.
Collapse
Ko B, et al. Abstract 3022. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Click Here to Manage Email Alerts